# Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

> **NCT06348134** · PHASE2 · RECRUITING · sponsor: **University of Chicago** · enrollment: 74 (estimated)

## Conditions studied

- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- HER2-positive Breast Cancer
- Breast Cancer

## Interventions

- **DRUG:** Trastuzumab emtansine
- **DRUG:** Pertuzumab Injection
- **DRUG:** Docetaxel
- **DRUG:** Tamoxifen
- **DRUG:** Letrozole
- **DRUG:** Goserelin

## Key facts

- **NCT ID:** NCT06348134
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-18
- **Primary completion:** 2034-07-01
- **Final completion:** 2036-07-01
- **Target enrollment:** 74 (ESTIMATED)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06348134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06348134, "Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06348134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*